Early dynamic PET imaging shows hypervascularization as exact as contrast-enhanced MR

• References

• 1 Ayyappan AP, Jhaveri KS. CT and MRI of hepatocellular carcinoma: an update. Expert Rev Anticancer Ther 2010; 10: 507-519.
• 2 Donati OF, Reiner CS, Hany TF. et al. ¹⁸F-FDG-PET and MRI in patients with malignancies of the liver and pancreas. Accuracy of retrospective multimodality image registration by using the CT-component of PET/CT. Nuklearmedizin 2010; 49: 106-114.
• 3 Hain SF, Fogelman I. Recent advances in imaging hepatocellular carcinoma: diagnosis, staging and response assessment: functional imaging. Cancer J 2004; 10: 121-127.
• 4 Kim TK, Lee KH, Khalili K, Jang HJ. Hepatocellular nodules in liver cirrhosis: contrast-enhanced ultrasound. Abdom Imaging 2011; 36: 244-263.
• 5 Kotzerke J, Oehme L, Lindner O, Hellwig D. Positron emission tomography 2008 in Germany – results of the query and current status. Nuklearmedizin 2010; 49: 58-64.
• 6 Salem N, Kuang Y, Wang F. et al. PET imaging of hepatocellular carcinoma with 2-deoxy-2[¹⁸F] - fluoro-D-glucose, 6-deoxy-6[¹⁸F] fluoro-Dglucose, [1–¹¹C]-acetate and [N-methyl-¹¹C]-choline. Q J Nucl Med Mol Imaging 2009; 53: 144-156.
• 7 Talbot JN, Fartoux L, Balogova S. et al. Detection of hepatocellular carcinoma with PET/CT: a prospective comparison of ¹⁸F-fluorocholine and ¹⁸F-FDG in patients with cirrhosis or chronic liver disease. J Nucl Med 2010; 51: 1699-1706.
• 8 Venook AP, Papandreou C, Furuse J, de Guevara LL. The incidence and epidemiology of hepatocellular carcinoma: a global and regional perspective. Oncologist 2010; 15 (Suppl. 04) 5-13.
• 9 Vilgrain V. Advancement in HCC imaging: diagnosis, staging and treatment efficacy assessments: hepatocellular carcinoma: imaging in assessing treatment efficacy. J Hepatobiliary Pancreat Sci 2010; 17: 374-379.